These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22681256)

  • 1. The early estimation of circulating drug metabolites in humans.
    Luffer-Atlas D
    Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):985-97. PubMed ID: 22681256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolites in safety testing.
    Robison TW; Jacobs A
    Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A regulatory perspective on issues and approaches in characterizing human metabolites.
    Davis-Bruno KL; Atrakchi A
    Chem Res Toxicol; 2006 Dec; 19(12):1561-3. PubMed ID: 17173368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meeting the MIST regulations: human metabolism in Phase I using AMS and a tiered bioanalytical approach.
    Lappin G; Seymour M; Gross G; Jørgensen M; Kall M; Kværnø L
    Bioanalysis; 2012 Feb; 4(4):407-16. PubMed ID: 22394141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
    Walker D; Brady J; Dalvie D; Davis J; Dowty M; Duncan JN; Nedderman A; Obach RS; Wright P
    Chem Res Toxicol; 2009 Oct; 22(10):1653-62. PubMed ID: 19715349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategy for genotoxicity testing--metabolic considerations.
    Ku WW; Bigger A; Brambilla G; Glatt H; Gocke E; Guzzie PJ; Hakura A; Honma M; Martus HJ; Obach RS; Roberts S;
    Mutat Res; 2007 Feb; 627(1):59-77. PubMed ID: 17141553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s.
    Powley MW; Frederick CB; Sistare FD; DeGeorge JJ
    Chem Res Toxicol; 2009 Feb; 22(2):257-62. PubMed ID: 19170595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary?
    Obach RS; Nedderman AN; Smith DA
    Xenobiotica; 2012 Jan; 42(1):46-56. PubMed ID: 21992031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolites in safety testing: metabolite identification strategies in discovery and development.
    Nedderman AN
    Biopharm Drug Dispos; 2009 May; 30(4):153-62. PubMed ID: 19544286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting circulating human metabolites: how good are we?
    Anderson S; Luffer-Atlas D; Knadler MP
    Chem Res Toxicol; 2009 Feb; 22(2):243-56. PubMed ID: 19138063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites.
    Prueksaritanont T; Lin JH; Baillie TA
    Toxicol Appl Pharmacol; 2006 Dec; 217(2):143-52. PubMed ID: 17055014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interpretation and considerations on the safety evaluation of human drug metabolites.
    Atrakchi AH
    Chem Res Toxicol; 2009 Jul; 22(7):1217-20. PubMed ID: 19563206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolites and safety: What are the concerns, and how should we address them?
    Smith DA; Obach RS
    Chem Res Toxicol; 2006 Dec; 19(12):1570-9. PubMed ID: 17173370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety assessment of drug metabolites: Characterization of chemically stable metabolites.
    Humphreys WG; Unger SE
    Chem Res Toxicol; 2006 Dec; 19(12):1564-9. PubMed ID: 17173369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.
    Gómez-Lechón MJ; Castell JV; Donato MT
    Chem Biol Interact; 2007 May; 168(1):30-50. PubMed ID: 17134688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
    Srinivas NR
    Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction: Human metabolites in safety testing (MIST) issue.
    Guengerich FP
    Chem Res Toxicol; 2009 Feb; 22(2):237-8. PubMed ID: 19216576
    [No Abstract]   [Full Text] [Related]  

  • 18. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment.
    Smith DA; Obach RS
    Chem Res Toxicol; 2009 Feb; 22(2):267-79. PubMed ID: 19166333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regioselective biotransformation of CNS drugs and its clinical impact on adverse drug reactions.
    Wong YC; Qian S; Zuo Z
    Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):833-54. PubMed ID: 22568396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.
    Dalvie D; Obach RS; Kang P; Prakash C; Loi CM; Hurst S; Nedderman A; Goulet L; Smith E; Bu HZ; Smith DA
    Chem Res Toxicol; 2009 Feb; 22(2):357-68. PubMed ID: 19146377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.